The use case: how Manas AI deploys Causaly
Manas AI uses Causaly as its primary platform for target identification and validation in drug discovery, running evidence assessments across human genetics, preclinical, clinical, competitor and safety data before committing resources to a target. It also uses the platform as a sanity check at later pipeline stages.
In the customer’s words
Companies live and die based on the identification and veracity of their targets. If you make a mistake at the very first step, every step that follows will be a snowball effect from that initial wrong decision.Causaly users in Biotech & Pharma
Companies in the same sector, with public evidence.
See all Causaly customersGo straight to the source
Based on Causaly’s published case study. We check the public evidence; the results are reported by the vendor.
causaly.com- Source published
- Jun 29, 2026
- Last checked
- Oct 8, 2026
Open source capture What the story claims, and what we checked
What we compared with the page.
- The passage quoted aboveChecked
Copied word for word from the page, near the name of Manas AI.
- The publication dateChecked
Read from the page’s own metadata, never guessed.
- Manas AI uses CausalyChecked
Confirmed line.
- The result itselfNot checked
We quote it; we did not measure it.
Manas AI uses Causaly as its primary platform for target identification and validation. When a candidate target is identified, whether starting from a disease pathway or from a protein family with known druggability, the team uses Causaly to run a comprehensive evidence assessment before committing resources.






